Toll Brothers
TOL
Meritage Homes
MTH
Taylor Morrison Home
TMHC
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
ONCT Oncternal Therapeutics
- 0.5266
- 0.00000.00%
Close Dec 2 16:00 ET
1.56MMarket Cap-0.05P/E (TTM)
0.0000High0.0000Low0Volume0.0000Open0.5266Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)2.96MShares10.613052wk High0.17P/B1.43MFloat Cap0.526652wk Low--Dividend TTM2.71MShs Float3583.9949Historical High--Div YieldTTM0.00%Amplitude0.5260Historical Low--Avg Price1Lot Size
Oncternal Therapeutics News
Oncternal Therapeutics Cut to Market Perform From Outperform by Northland Capital Markets
Oncternal Therapeutics Price Target Announced at $2.00/Share by Northland Capital Markets
Oncternal Therapeutics Analyst Ratings
Brookline Capital Maintains Oncternal Therapeutics(ONCT.US) With Hold Rating
Oncternal Therapeutics Price Target Cut to $18.00/Share From $19.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18
Oncternal Therapeutics Analyst Ratings
Oncternal Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
Oncternal Therapeutics' Positive Clinical Progress and Future Catalysts Underpin Buy Rating
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $28.00 to $19.00.
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $28.00.
Oncternal Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.